Dr. Reddy's Laboratories Ltd.

  • Home
  • Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd. We are a global pharmaceutical company committed to providing affordable & innovative medicines. Dr. Reddy’s Laboratories Ltd.

(BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first
Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Dr. Reddy’s does not collect nor does it require you to share any personal data or personal information, towards your access to or participation in the Facebook event organised by it. You are advised to not disclose any personally identifiable or confidential or non-public information on social media; you are personally responsible for any data that you may decide to share or post on any social media including on this page and Dr. Reddy’s owes no duty or obligation or liability to you or to any other person for the same. All participants on this Facebook event are required to behave with courtesy to others and to not post any offensive/objectionable messages or to intrude into any other person’s rights of privacy.

Our Chairman, Satish Reddy, on the proposed India–US interim trade agreement and its potential to enable new opportuniti...
09/02/2026

Our Chairman, Satish Reddy, on the proposed India–US interim trade agreement and its potential to enable new opportunities for Indian industry.

For years, animal models have been the default in drug development. They have helped science move forward, but they have...
09/02/2026

For years, animal models have been the default in drug development. They have helped science move forward, but they have also shown limits, especially in high failure rates and time lost for patients.

A multistakeholder study, “Landscape Analysis on Alternatives to Animal Testing for Drug Development in India”, jointly developed in association with Humane World for Animals India, DBT-InSTEM, Animal Law and Policy Network highlights how non animal, human relevant methods can strengthen research while supporting better outcomes for patients and reducing harm to animals.

If you care about animals, science, research quality, and access to better medicines, read the complete article. Link to digital edition is in comments.

We have received the Gold Shield at the ICAI Awards for Excellence in Financial Reporting 2024-25, conferred by the The ...
07/02/2026

We have received the Gold Shield at the ICAI Awards for Excellence in Financial Reporting 2024-25, conferred by the The Institute of Chartered Accountants of India (ICAI) in the Manufacturing and Trading category for organisations with a turnover of ₹5,000 crore and above.

The honour recognises quality of our financial reporting, transparency and adherence to the highest standards of accounting and disclosure practices.

04/02/2026

On , our leaders reflect on the responsibility behind decisions shaping care, outcomes, and progress in the fight against cancer.

This conversation matters because in pharma, leadership choices shape research priorities, access to care, affordability, and how treatment evolves for patients.

More in the video!

India’s pharmaceutical sector is entering a decisive phase, moving from volume-led growth to value-driven, innovation-le...
02/02/2026

India’s pharmaceutical sector is entering a decisive phase, moving from volume-led growth to value-driven, innovation-led leadership.

In a recently published column in Business Standard, our chairman Satish Reddy outlines how Union Budget 2026 strengthens India’s focus on biologics, biosimilars, clinical research infrastructure and human capital—key enablers for accelerating this transition. Strengthening domestic capabilities, expanding accredited trial networks and enabling regulatory agility will be critical to translating science into patient impact.

As India advances toward its ambition of becoming a global biopharma hub, aligning innovation with affordability, access and sustainability remains central—because good health must reach those who need it most.

We announced the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), in the United ...
16/01/2026

We announced the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), in the United States. This antihistamine eye drop is indicated for the temporary relief of itchy eyes caused by pollen, ragweed, grass, animal hair, and dander.

This launch also strengthens our OTC eye-care portfolio, which includes Olopatadine Hydrochloride Ophthalmic Solution USP in 0.2% and 0.1% strengths.

With every product, we continue our commitment to improving access and affordability of innovative treatments, as we progress toward our goal of serving over 1.5 billion patients by 2030.

Click here to read more: https://shorturl.at/sBBrg

LThe Indian Pharmaceutical Alliance (IPA) has announced the launch of Pharma Academy for Global Excellence (PAGE), with ...
13/01/2026

LThe Indian Pharmaceutical Alliance (IPA) has announced the launch of Pharma Academy for Global Excellence (PAGE), with its groundbreaking ceremony held in Sanathal, Ahmedabad. This initiative aims to address the evolving skill requirements of the pharmaceutical industry.

Speaking at the event, our chairman, Satish Reddy, highlighted the need for continuous upskilling in light of rapid technological advancements and rising patient safety standards. He shared that PAGE is designed as an industry-aligned skilling platform to make fresh graduates industry-ready from day one and enable professionals to reskill and upskill in line with evolving regulatory and manufacturing realities.

He further explained how this initiative will strengthen India's position as a trusted global supplier of medicines by creating a workforce that understands quality as a system and compliance as a culture.

Guests at the ceremony included Shri Amit Shah, Hon’ble Union Minister of Home Affairs and Minister of Cooperation, Government of India, and Hon’ble Chief Minister of Gujarat, Shri Bhupendra Patel.

We’re in San Francisco for the 44th Annual J.P. Morgan Healthcare Conference—engaging in conversations that matter: shap...
13/01/2026

We’re in San Francisco for the 44th Annual J.P. Morgan Healthcare Conference—engaging in conversations that matter: shaping the future of healthcare through innovation, expanding access and affordability, and ensuring quality patients can trust.

Our leaders are exploring partnerships and ideas to turn these commitments into reality—because advancing global health isn’t just a vision, it’s a responsibility we live every day.

We announce the launch of Hevaxin®️, the only vaccine approved by the Drug Controller General of India (DCGI) for active...
07/01/2026

We announce the launch of Hevaxin®️, the only vaccine approved by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65 years in the country.

This is a significant milestone, especially in light of the global burden of Hepatitis E. According to the World Health Organization (WHO), the virus infects nearly 20 million people annually, leading to 3.4 million illnesses, 70,000 deaths, and an estimated 3,000 stillbirths worldwide.

Those most at risk include:

•Women of childbearing age
•Patients with chronic liver disease
•Individuals with weakened immunity
•Patients preparing for organ transplantation

With every product, we continue our commitment to drive access and affordability of innovative healthcare solutions, as part of our journey to serve over 1.5 billion patients by 2030.

Click to read more: https://shorturl.at/mtOxw


(Good Health and Well-being)

31/12/2025

As we look back at 2025, we see a year filled with celebrating excellence, people, science, innovation, and a commitment to patients and customers across the globe.

We wrap up the year with a deep sense of gratitude and a clear focus for the year ahead.

Many of you played a critical role in our journey as partners, shareholders, customers and well-wishers. We thank you for your trust and support.

We wish all of you a Happy New Year filled with good health and prosperity.

Honoured to share that our Chairman, Satish Reddy, was part of the official business delegation to Oman led by Hon’ble P...
22/12/2025

Honoured to share that our Chairman, Satish Reddy, was part of the official business delegation to Oman led by Hon’ble Prime Minister Shri Narendra Modi.

He participated in the India–Oman Business Forum alongside Indian and Omani CEOs, focusing on strengthening collaboration in healthcare and pharmaceuticals.

The visit also witnessed the signing of the India–Oman Comprehensive Economic Partnership Agreement (CEPA) in the presence of the Prime Minister—a significant step toward deepening bilateral ties and advancing shared priorities in critical sectors.

Address

Dr. Reddy's Laboratories Limited (Corporate Office), Door No 8-2-337, Road No 3, Banjara Hills, Hyderabad.

500034

Website

Alerts

Be the first to know and let us send you an email when Dr. Reddy's Laboratories Ltd. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

  • Want your practice to be the top-listed Clinic?

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram